A prospective multicentre study of discontinuing prophylaxis for opportunistic infections after effective antiretroviral therapy
Authors:
- P HayPHP Hay
- on behalf of the STOPIT InvestigatorsOIon behalf of the STOPIT Investigators
- 1 July 2004
- journal article
- research article
- Published by Wiley in HIV Medicine
- Vol. 5 (4) , 278-283
Abstract
To assess the medium-term safety of discontinuing prophylaxis (primary or secondary) for opportunistic infections following an effective response to antiretroviral therapy.Participating clinical sites prospectively identified patients in whom the discontinuation of prophylaxis for any opportunistic infection was considered to be clinically indicated, although CD4 levels were not predefined. A follow-up report was subsequently sent every 6 months requesting information on changes in prophylaxis, antiretroviral drugs, new AIDS-defining events, and CD4 cell count results.Prophylaxis for Pneumocystis carinii pneumonia (PCP) was withdrawn in 524 patients (426 primary and 98 secondary prophylaxis), prophylaxis for Mycobacterium avium complex (MAC) was withdrawn in 28 patients (13 primary and 15 secondary), and prophylaxis for cytomegalovirus (CMV) retinitis was withdrawn in 10 patients. CD4 counts were generally maintained above accepted prophylaxis threshold levels during the period of follow up (95-98% of the time). Total follow up to last report or re-continuation of prophylaxis was 680 and 144 person-years for patients discontinuing primary and secondary PCP prophylaxis, respectively. No cases of PCP were reported, giving incidence rates of 0.0 (upper 95% confidence limit 0.4) and 0.0 (2.1) per 100 person-years. No cases of MAC were reported, but one patient had a recurrence of CMV retinitis. PCP prophylaxis was restarted in 30 patients; no patients restarted MAC or CMV prophylaxis.Previous studies have demonstrated a low risk of PCP in the short term following the withdrawal of prophylaxis in patients who have responded well to antiretroviral therapy. The present study suggests a continuing low level of risk with extended follow up, provided adequate CD4 count levels are maintained. The case of recurrent CMV retinitis in a patient with impressive immunological and virological response indicates the need for close monitoring of patients previously diagnosed with this condition.Keywords
This publication has 15 references indexed in Scilit:
- Discontinuation of Secondary Prophylaxis forPneumocystis cariniiPneumonia in Human Immunodeficiency Virus–Infected Patients: A Randomized Trial by the CIOP Study GroupClinical Infectious Diseases, 2003
- Safe Interruption of Maintenance Therapy against Previous Infection with Four Common HIV-Associated Opportunistic Pathogens during Potent Antiretroviral TherapyAnnals of Internal Medicine, 2002
- Discontinuation of Secondary Prophylaxis against Disseminated Mycobacterium avium Complex Infection and Toxoplasmic EncephalitisClinical Infectious Diseases, 2002
- A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to > 200 × 106/lAIDS, 2001
- Discontinuation of primary prophylaxis in HIV-infected patients at high risk of Pneumocystis carinii pneumonia: prospective multicentre studyAIDS, 2001
- Discontinuation of Secondary Prophylaxis againstPneumocystis cariniiPneumonia in Patients with HIV Infection Who Have a Response to Antiretroviral TherapyNew England Journal of Medicine, 2001
- A Randomized Trial of the Discontinuation of Primary and Secondary Prophylaxis againstPneumocystis cariniiPneumonia after Highly Active Antiretroviral Therapy in Patients with HIV InfectionNew England Journal of Medicine, 2001
- Discontinuing or withholding primary prophylaxis against Mycobacterium avium in patients on successful antiretroviral combination therapy. The Swiss HIV Cohort StudyAIDS, 2000
- Discontinuation of Prophylaxis againstMycobacterium aviumComplex Disease in HIV-Infected Patients Who Have a Response to Antiretroviral TherapyNew England Journal of Medicine, 2000
- AIDS-Related Opportunistic Illnesses Occurring After Initiation of Potent Antiretroviral TherapyJAMA, 1999